Quick Takeaways
- Oncorus, Inc. has 17 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are not currently available.
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 15 Apr 2025.
$0
Shares: 0
Insiders: 0
$0
Shares: 0
Insiders: 0
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Barbara Yanni | Director | Mixed | 23 Jun 2022 | |||
| James E. Flynn | Possible Member of 10% Group, 10%+ Owner | Mixed | 28 Dec 2022 | |||
| Mary Kay Fenton | Director | Mixed | 23 Jun 2022 | |||
| Rick Wanstall | CFO and Treasurer | Mixed | 25 May 2022 | |||
| Douglas Fambrough | Director | Mixed | 22 Jun 2022 | |||
| Mitchell H. Finer | Director | Mixed | 23 Jun 2022 | |||
| Theodore Ashburn | President and CEO, Director | Mixed | 01 Mar 2022 | |||
| John P. McCabe | CFO and Treasurer | Mixed | 01 Mar 2022 | |||
| Christophe Queva | CSO and SVP, Research | Mixed | 01 Mar 2022 | |||
| Stephen Harbin | COO and Chief of Staff | Mixed | 01 Nov 2022 | |||
| Eric Rubin | Director | Mixed | 23 Jun 2022 | |||
| Spencer Nam | Director | Mixed | 23 Jun 2022 | |||
| John Mayer Goldberg | Chief Medical Officer | Mixed | 01 Mar 2022 | |||
| Brian J. Shea | Interim CEO | Mixed | 06 Jun 2023 | |||
| Luke Evnin | Director | Mixed | 23 Jun 2022 | |||
| Scott A. Canute | Director | Mixed | 23 Jun 2022 | |||
| Alexander Nolte | Interim CFO | Mixed | 09 May 2023 |
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| James E. Flynn |
3/4/5
|
Possible Member of 10% Group, 10%+ Owner |
—
class O/S missing
|
2,597,314
|
— | — | 28 Dec 2022 | |
| Theodore Ashburn |
3/4/5
|
President and CEO, Director |
—
class O/S missing
|
211,000
|
— | — | 01 Mar 2022 | |
| Stephen Harbin |
3/4/5
|
COO and Chief of Staff |
—
class O/S missing
|
150,000
|
— | — | 01 Nov 2022 | |
| John P. McCabe |
3/4/5
|
CFO and Treasurer |
—
class O/S missing
|
90,000
|
— | — | 01 Mar 2022 | |
| John Mayer Goldberg |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
84,500
|
— | — | 01 Mar 2022 | |
| Christophe Queva |
3/4/5
|
CSO and SVP, Research |
—
class O/S missing
|
82,500
|
— | — | 01 Mar 2022 | |
| Rick Wanstall |
3/4/5
|
CFO and Treasurer |
—
class O/S missing
|
51,000
|
— | — | 25 May 2022 | |
| Douglas Fambrough |
3/4/5
|
Director |
—
class O/S missing
|
25,000
|
— | — | 22 Jun 2022 | |
| Barbara Yanni |
3/4/5
|
Director |
—
class O/S missing
|
12,500
|
— | — | 23 Jun 2022 | |
| Eric Rubin |
3/4/5
|
Director |
—
class O/S missing
|
12,500
|
— | — | 23 Jun 2022 | |
| Luke Evnin |
3/4/5
|
Director |
—
class O/S missing
|
12,500
|
— | — | 23 Jun 2022 | |
| Mary Kay Fenton |
3/4/5
|
Director |
—
class O/S missing
|
12,500
|
— | — | 23 Jun 2022 | |
| Mitchell H. Finer |
3/4/5
|
Director |
—
class O/S missing
|
12,500
|
— | — | 23 Jun 2022 | |
| Scott A. Canute |
3/4/5
|
Director |
—
class O/S missing
|
12,500
|
— | — | 23 Jun 2022 | |
| Spencer Nam |
3/4/5
|
Director |
—
class O/S missing
|
12,500
|
— | — | 23 Jun 2022 | |
| Brian J. Shea |
3/4/5
|
Interim CEO |
—
class O/S missing
|
8,541
|
— | — | 06 Jun 2023 |
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||